The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo

There are few available treatments for hormone refractory prostate cancer. Through the inhibition of integrins, contortrostatin (CN) effects tumor cell growth directly as well as through the inhibition of angiogenesis. The effect of CN in combination with docetaxel on prostate cancer cell lines in vitro and in vivo is evaluated in the present study.

[1]  Swapnika Ramu,et al.  Anti-angiogenesis and RGD-containing snake venom disintegrins. , 2007, Current pharmaceutical design.

[2]  T. Byzova,et al.  Prostate cancer specific integrin αvβ3 modulates bone metastatic growth and tissue remodeling , 2007, Oncogene.

[3]  R. Baron,et al.  Tumor αvβ3 Integrin Is a Therapeutic Target for Breast Cancer Bone Metastases , 2007 .

[4]  C. Liang,et al.  In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro , 2007, Nature Protocols.

[5]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[6]  David Zurakowski,et al.  A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. , 2006, Journal of the National Cancer Institute.

[7]  F. Markland,et al.  Contortrostatin, a Snake Venom Disintegrin with Anti-Angiogenic and Anti-Tumor Activity , 2006, Pathophysiology of Haemostasis and Thrombosis.

[8]  R. Nagle,et al.  Characterization of integrin subunits, cellular adhesion and tumorgenicity of four human prostate cell lines , 1993, Journal of Cancer Research and Clinical Oncology.

[9]  A. Mercurio,et al.  Contributions of the alpha6 integrins to breast carcinoma survival and progression. , 2004, Molecules and cells.

[10]  R. Sherwin,et al.  Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression. , 2004, Molecular cancer therapeutics.

[11]  R. Nagle,et al.  Integrin α6 expression in human prostate carcinoma cells is associated with a migratory and invasive phenotypein vitro andin vivo , 1995, Clinical & Experimental Metastasis.

[12]  S. Dedhar,et al.  Specific alterations in the expression of α3β1 and α6β4 integrins in highly invasive and metastatic variants of human prostate carcinoma cells selected by in vitro invasion through reconstituted basement membrane , 1993, Clinical & Experimental Metastasis.

[13]  M. Trikha,et al.  Inhibition of αvβ3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases , 2004, Clinical & Experimental Metastasis.

[14]  F. Markland,et al.  Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits angiogenesis , 2004, Angiogenesis.

[15]  F. Scappaticci.  Mechanisms and future directions for angiogenesis-based cancer therapies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. Shono,et al.  Inhibition of FGF-2-mediated chemotaxis of murine brain capillary endothelial cells by cyclic RGDfV peptide through blocking the redistribution of c-Src into focal adhesions. , 2001, Experimental cell research.

[17]  G. Laurie,et al.  Integrin expression and usage by prostate cancer cell lines on laminin substrata. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[18]  Jung Weon Lee,et al.  New aspects of integrin signaling in cancer. , 2000, Seminars in cancer biology.

[19]  F. Markland,et al.  Contortrostatin, a snake venom disintegrin, induces αvβ3‐mediated tyrosine phosphorylation of CAS and FAK in tumor cells , 2000 .

[20]  T. Byzova,et al.  A mechanism for modulation of cellular responses to VEGF: activation of the integrins. , 2000, Molecular cell.

[21]  G. Davis,et al.  RGD-Dependent Vacuolation and Lumen Formation Observed during Endothelial Cell Morphogenesis in Three-Dimensional Fibrin Matrices Involves the αvβ3 and α5β1 Integrins , 2000 .

[22]  H. Moch,et al.  Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. , 2000, Human pathology.

[23]  P. Brooks,et al.  Contortrostatin, a Homodimeric Disintegrin, Binds to Integrin αvβ5 , 2000 .

[24]  Q. Zhou,et al.  Contortrostatin, a snake venom disintegrin, induces alphavbeta3-mediated tyrosine phosphorylation of CAS and FAK in tumor cells. , 2000, Journal of cellular biochemistry.

[25]  Q. Zhou,et al.  Contortrostatin, a homodimeric disintegrin, binds to integrin alphavbeta5. , 2000, Biochemical and biophysical research communications.

[26]  S. Groshen,et al.  Contortrostatin, a dimeric disintegrin from Agkistrodon contortrix contortrix, inhibits breast cancer progression. , 2000, Breast cancer research and treatment.

[27]  G. Davis,et al.  RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the alpha(v)beta(3) and alpha(5)beta(1) integrins. , 2000, The American journal of pathology.

[28]  A. Woodard,et al.  Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. , 1999, Cancer research.

[29]  E. Thompson,et al.  Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the αvβ3 and αvβ5 integrins , 1998 .

[30]  R. Klemke,et al.  Integrin αvβ3 Requirement for Sustained Mitogen-activated Protein Kinase Activity during Angiogenesis , 1998, The Journal of cell biology.

[31]  Marco Presta,et al.  αvβ3 Integrin Mediates the Cell-adhesive Capacity and Biological Activity of Basic Fibroblast Growth Factor (FGF-2) in Cultured Endothelial Cells , 1997 .

[32]  Thomas Boehm,et al.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.

[33]  M. Schwartz.  Integrins, Oncogenes, and Anchorage Independence , 1997, The Journal of cell biology.

[34]  C. Garlanda,et al.  Involvement of endothelial PECAM-1/CD31 in angiogenesis. , 1997, The American journal of pathology.

[35]  P. L. Haywood-Reid,et al.  Quantification of integrin subunits on human prostatic cell lines—Comparison of nontumorigenic and tumorigenic lines , 1997, The Prostate.

[36]  P. Dell’Era,et al.  alphavbeta3 integrin mediates the cell-adhesive capacity and biological activity of basic fibroblast growth factor (FGF-2) in cultured endothelial cells. , 1997, Molecular biology of the cell.

[37]  David A. Cheresh,et al.  Definition of Two Angiogenic Pathways by Distinct αv Integrins , 1995, Science.

[38]  R. Pardi,et al.  The platelet endothelial cell adhesion molecule‐1 (PECAM1) contributes to endothelial barrier function , 1995, FEBS letters.

[39]  J. Brugge,et al.  Integrins and signal transduction pathways: the road taken. , 1995, Science.

[40]  L Piana,et al.  CD31 quantitative immunocytochemical assays in breast carcinomas. Correlation with current prognostic factors. , 1995, American journal of clinical pathology.

[41]  D. Cheresh,et al.  Definition of two angiogenic pathways by distinct alpha v integrins. , 1995, Science.

[42]  D. Cheresh,et al.  Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels , 1994, Cell.

[43]  M. Trikha,et al.  Contortrostatin, a snake venom disintegrin, inhibits beta 1 integrin-mediated human metastatic melanoma cell adhesion and blocks experimental metastasis. , 1994, Cancer research.

[44]  D. Cheresh,et al.  Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. , 1994, Cell.

[45]  M. Trikha,et al.  Purification and characterization of platelet aggregation inhibitors from snake venoms. , 1994, Thrombosis research.

[46]  N. Weidner,et al.  Intratumoral microvessel density and L53 protein: Correlation with metastasis in head‐and‐neck squamous‐cell carcinoma , 1993, International journal of cancer.

[47]  J. Thiery,et al.  † Author for correspondence , 1693 .

[48]  S. Albelda,et al.  Platelet endothelial cell adhesion molecule, PECAM‐1, modulates cell migration , 1992, Journal of cellular physiology.

[49]  D. Cheresh.  Structural and biologic properties of integrin-mediated cell adhesion. , 1992, Clinics in laboratory medicine.

[50]  Richard O. Hynes,et al.  Integrins: Versatility, modulation, and signaling in cell adhesion , 1992, Cell.

[51]  M. Key,et al.  Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. , 1991, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[52]  L. Romer,et al.  EndoCAM: a novel endothelial cell-cell adhesion molecule , 1990, The Journal of cell biology.

[53]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[54]  J. Folkman,et al.  TUMOR DORMANCY IN VIVO BY PREVENTION OF NEOVASCULARIZATION , 1972, The Journal of experimental medicine.

[55]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.